CKD-5, a novel pan-histone deacetylase inhibitor, synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma

被引：0
|
作者：
Young Chang
Yun Bin Lee
Eun Ju Cho
Jeong-Hoon Lee
Su Jong Yu
Yoon Jun Kim
Jung-Hwan Yoon
机构：
[1] Department of Internal Medicine and Liver Research Institute,Institute for Digestive Research, Digestive Disease Center, Department of Internal Medicine
[2] Seoul National University College of Medicine,undefined
[3] Soonchunhyang University College of Medicine,undefined
来源：
BMC Cancer | / 20卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] First clinical data of resminostat, a novel oral histone deacetylase (HDAC) inhibitor, in patients with hepatocellular carcinoma (HCC): The SHELTER study
    Bitzer, M.
    Horger, M.
    Ebert, M. P.
    Ganten, T.
    Woerns, M. A.
    Hauns, B.
    Mais, A.
    Jankowsky, R.
    Hentsch, B.
    Lauer, U. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [42] A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent/metastatic sarcomas-NCIC-CTG IND 200
    Chu, Q. S. -C.
    Nielsen, T. O.
    Alcindor, T.
    Gupta, A.
    Endo, M.
    Goytain, A.
    Xu, H.
    Verma, S.
    Tozer, R.
    Knowling, M.
    Bramwell, V. B.
    Powers, J.
    Seymour, L. K.
    Eisenhauer, E. A.
    ANNALS OF ONCOLOGY, 2015, 26 (05) : 973 - 981
  • [43] JNJ-26481585, a novel "second-generation" oral pan-histone deacetylase (HDAC) inhibitor, shows broad-spectrum preclinical antitumoral activity against solid and hematological malignancies
    Arts, Janine
    Marien, Ann
    King, Peter
    Floren, Wim
    Belien, Ann
    Janssen, Lut
    Pilatte, Isabelle
    Roux, Bruno
    Decrane, Laurence
    Gilissen, Ron
    Andries, Luc
    Jung, Manfred
    Du Jardin, Marc
    Janicot, Michel
    van Emelen, Kristof
    Angibaud, Patrick
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3421S - 3422S
  • [44] Withaferin A, a natural thioredoxin reductase 1 (TrxR1) inhibitor, synergistically enhances the antitumor efficacy of sorafenib through ROS-mediated ER stress and DNA damage in hepatocellular carcinoma cells
    Chen, Xi
    Zhu, Ning
    Wu, Yajie
    Zhang, Ye
    Zhang, Yuxuan
    Jin, Kaiwen
    Zhou, Zhiyi
    Chen, Guang
    Wang, Jiabing
    PHYTOMEDICINE, 2024, 128
  • [45] Novel ADAM-17 inhibitor ZLDI-8 enhances the in vitro and in vivo chemotherapeutic effects of Sorafenib on hepatocellular carcinoma cells
    Yingshi Zhang
    Dandan Li
    Qiyu Jiang
    Shuang Cao
    Huiwei Sun
    Yantao Chai
    Xiaojuan Li
    Tianshu Ren
    Ruichuang Yang
    Fan Feng
    Bo-an Li
    Qingchun Zhao
    Cell Death & Disease, 9
  • [46] Novel ADAM-17 inhibitor ZLDI-8 enhances the in vitro and in vivo chemotherapeutic effects of Sorafenib on hepatocellular carcinoma cells
    Zhang, Yingshi
    Li, Dandan
    Jiang, Qiyu
    Cao, Shuang
    Sun, Huiwei
    Chai, Yantao
    Li, Xiaojuan
    Ren, Tianshu
    Yang, Ruichuang
    Feng, Fan
    Li, Bo-an
    Zhao, Qingchun
    CELL DEATH & DISEASE, 2018, 9
  • [47] A novel multitarget kinase inhibitor BZG with potent anticancer activity in vitro and vivo enhances efficacy of sorafenib through PI3K pathways in hepatocellular carcinoma cells
    Wang, Li
    Zhan, Yaqiong
    Wu, Zhe
    Lin, Mengjia
    Jin, Xuehang
    Jiang, Lushun
    Qiu, Yunqing
    BIOMEDICINE & PHARMACOTHERAPY, 2020, 125
  • [48] Phase IIa safety and efficacy of milciclib, a pan-cyclin dependent kinase inhibitor, in unresectable, sorafenib-refractory or -intolerant hepatocellular carcinoma patients.
    Villa, Erica
    Piscaglia, Fabio
    Geva, Rabit
    Dalecos, George
    Papatheodoridis, George
    Ciomei, Marina
    Davite, Christina
    Crivori, Patrizia
    Palejwala, Vaseem
    Jacob, Jules
    Hamzeh, Fayez
    Shailubhai, Kunwar
    Santoro, Armando
    Sangiovanni, Angelo
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [49] Treatment with β-Catenin Antagonist BC2059 Exerts Single Agent Efficacy and Exerts Improved Activity with Tyrosine Kinase Inhibitor (TKI) or Pan-Histone Deacetylase (HDAC) Inhibitor Against Human CML and Myeloproliferative Neoplasm (MPN) Progenitor Cells
    Fiskus, Warren
    Smith, Jacqueline
    Mudunuru, Uma
    Hembruff, Stacey
    Reyes, Ruben
    Abhyankar, Sunil
    McGuirk, Joseph
    Aljitawi, Omar S.
    Ganguly, Siddhartha
    Horrigan, Stephen K.
    Sharma, Sunil
    Bhalla, Kapil N.
    BLOOD, 2011, 118 (21) : 31 - 31
  • [50] Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma
    Mi Na Kim
    Seung Min Lee
    Jin Sung Kim
    Seong Gyu Hwang
    Cancer Chemotherapy and Pharmacology, 2019, 84 : 809 - 817
12345